Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Cardiff Oncology, Inc. | a12-9768_14ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 30, 2012
Trovagene, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
27-2004382 |
|
(State or other jurisdiction |
|
IRS Employer |
|
of incorporation or organization) |
|
Identification No.) |
11055 Flintkote Avenue, Suite B
San Diego, CA 92121
(Address of principal executive offices)
Registrant’s telephone number, including area code: (858) 217-4838
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On May 30, 2012, Trovagene, Inc. (the “Company”) issued a press release announcing (i) the pricing of its public offering of 1,150,000 units (the “Units”) at $8.00 per Unit; (ii) the listing of the Company’s Common Stock on The NASDAQ Capital Market under the symbol “TROV”; and (iii) the effectiveness of the reverse split of the Company’s outstanding common stock on a one-for six basis. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
|
99.1 |
Press Release dated May 30, 2012 |